RxDoctor Payments Data

Mark Hite, MD

Ophthalmology · Queensbury, NYNPI 1366488025

Payments from drug & device makers

$7,152in general payments, 2019–2025

Across 298 payments — averaging $24.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Alcon$1K
  • Bausch & Lomb Americas Inc.$542
  • Oyster Point Pharma, Inc.$505
  • Biotissue Holdings Inc.$440
  • Sight Sciences, Inc.$370
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$7,10699%
  • Education$401%
  • Entertainment$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,152 in reported general payments places this provider in the 80th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$345,003
Medicare patients
1,155
Services billed
3,222

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost157$104,276
RestasisCyclosporine50$72,981
Cyclosporine56$30,616
CombiganBrimonidine Tartrate/Timolol41$21,251
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol99$18,241
RhopressaNetarsudil Mesylate12$11,660
SimbrinzaBrinzolamide/Brimonidine Tart32$10,881
Latanoprost771$10,600
XalatanLatanoprost14$10,547
Prednisolone Acetate157$5,798
Travoprost31$5,028
Bromfenac Sodium22$4,242
Brinzolamide20$4,191
Timolol Maleate224$3,742
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat132$2,288

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$1,679$198,507248 claims
Aerie Pharmaceuticals, Inc.Rhopressa$368$11,66012 claims
AlconSimbrinza$1,275$10,88132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Queensbury

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →